Logo image of TLRY.CA

TILRAY BRANDS INC (TLRY.CA) Stock Fundamental Analysis

TSX:TLRY - Toronto Stock Exchange - US88688T1007 - Common Stock - Currency: CAD

0.6  -0.02 (-3.23%)

Fundamental Rating

3

Taking everything into account, TLRY scores 3 out of 10 in our fundamental rating. TLRY was compared to 33 industry peers in the Pharmaceuticals industry. The financial health of TLRY is average, but there are quite some concerns on its profitability. While showing a medium growth rate, TLRY is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

TLRY had negative earnings in the past year.
TLRY had a negative operating cash flow in the past year.
TLRY had negative earnings in each of the past 5 years.
TLRY had negative operating cash flow in 4 of the past 5 years.
TLRY.CA Yearly Net Income VS EBIT VS OCF VS FCFTLRY.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 -500M -1B

1.2 Ratios

TLRY has a worse Return On Assets (-27.79%) than 66.67% of its industry peers.
Looking at the Return On Equity, with a value of -34.64%, TLRY is in line with its industry, outperforming 42.42% of the companies in the same industry.
Industry RankSector Rank
ROA -27.79%
ROE -34.64%
ROIC N/A
ROA(3y)-16.09%
ROA(5y)-22.56%
ROE(3y)-20.59%
ROE(5y)-49.37%
ROIC(3y)N/A
ROIC(5y)N/A
TLRY.CA Yearly ROA, ROE, ROICTLRY.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 0 100 -100 -200 -300

1.3 Margins

The Gross Margin of TLRY (30.88%) is comparable to the rest of the industry.
TLRY's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for TLRY so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 30.88%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y34.12%
GM growth 5Y-3.12%
TLRY.CA Yearly Profit, Operating, Gross MarginsTLRY.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100 -150 -200

More info and screens

4

2. Health

2.1 Basic Checks

TLRY does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for TLRY has been increased compared to 1 year ago.
Compared to 5 years ago, TLRY has more shares outstanding
Compared to 1 year ago, TLRY has an improved debt to assets ratio.
TLRY.CA Yearly Shares OutstandingTLRY.CA Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M
TLRY.CA Yearly Total Debt VS Total AssetsTLRY.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B 4B 5B

2.2 Solvency

Based on the Altman-Z score of -0.77, we must say that TLRY is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of TLRY (-0.77) is comparable to the rest of the industry.
A Debt/Equity ratio of 0.11 indicates that TLRY is not too dependend on debt financing.
TLRY's Debt to Equity ratio of 0.11 is fine compared to the rest of the industry. TLRY outperforms 66.67% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.11
Debt/FCF N/A
Altman-Z -0.77
ROIC/WACCN/A
WACC8.65%
TLRY.CA Yearly LT Debt VS Equity VS FCFTLRY.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 1B 2B 3B 4B

2.3 Liquidity

A Current Ratio of 2.62 indicates that TLRY has no problem at all paying its short term obligations.
The Current ratio of TLRY (2.62) is better than 63.64% of its industry peers.
TLRY has a Quick Ratio of 1.61. This is a normal value and indicates that TLRY is financially healthy and should not expect problems in meeting its short term obligations.
The Quick ratio of TLRY (1.61) is better than 60.61% of its industry peers.
Industry RankSector Rank
Current Ratio 2.62
Quick Ratio 1.61
TLRY.CA Yearly Current Assets VS Current LiabilitesTLRY.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

More info and screens

5

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 25.41% over the past year.
TLRY shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 11.23%.
TLRY shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 78.86% yearly.
EPS 1Y (TTM)25.41%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%20%
Revenue 1Y (TTM)11.23%
Revenue growth 3Y55.33%
Revenue growth 5Y78.86%
Sales Q2Q%-1.36%

3.2 Future

TLRY is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 17.04% yearly.
Based on estimates for the next years, TLRY will show a small growth in Revenue. The Revenue will grow by 5.90% on average per year.
EPS Next Y-222.48%
EPS Next 2Y17.62%
EPS Next 3Y21.07%
EPS Next 5Y17.04%
Revenue Next Year8.45%
Revenue Next 2Y7.11%
Revenue Next 3Y5.97%
Revenue Next 5Y5.9%

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
TLRY.CA Yearly Revenue VS EstimatesTLRY.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M 1B
TLRY.CA Yearly EPS VS EstimatesTLRY.CA Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -0.5 -1 -1.5 -2

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

TLRY reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year TLRY is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TLRY.CA Price Earnings VS Forward Price EarningsTLRY.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 5 10 15 20 25

4.2 Price Multiples

63.64% of the companies in the same industry are more expensive than TLRY, based on the Enterprise Value to EBITDA ratio.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 19.51
TLRY.CA Per share dataTLRY.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2 3

4.3 Compensation for Growth

A more expensive valuation may be justified as TLRY's earnings are expected to grow with 21.07% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y17.62%
EPS Next 3Y21.07%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for TLRY!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

TILRAY BRANDS INC

TSX:TLRY (5/23/2025, 7:00:00 PM)

0.6

-0.02 (-3.23%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)04-08 2025-04-08/bmo
Earnings (Next)07-28 2025-07-28/amc
Inst Owners11.8%
Inst Owner ChangeN/A
Ins Owners0.29%
Ins Owner ChangeN/A
Market Cap615.32M
Analysts72.22
Price Target1.78 (196.67%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-140.2%
Min EPS beat(2)-145.1%
Max EPS beat(2)-135.29%
EPS beat(4)0
Avg EPS beat(4)-91.89%
Min EPS beat(4)-145.1%
Max EPS beat(4)-8.93%
EPS beat(8)1
Avg EPS beat(8)-85.68%
EPS beat(12)1
Avg EPS beat(12)-398.32%
EPS beat(16)4
Avg EPS beat(16)-256.75%
Revenue beat(2)0
Avg Revenue beat(2)-8.97%
Min Revenue beat(2)-13.28%
Max Revenue beat(2)-4.66%
Revenue beat(4)0
Avg Revenue beat(4)-7.31%
Min Revenue beat(4)-13.28%
Max Revenue beat(4)-0.75%
Revenue beat(8)1
Avg Revenue beat(8)-2.67%
Revenue beat(12)1
Avg Revenue beat(12)-3.36%
Revenue beat(16)1
Avg Revenue beat(16)-7.96%
PT rev (1m)-35.96%
PT rev (3m)-36.67%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-150%
EPS NY rev (1m)-5.05%
EPS NY rev (3m)-439.02%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-8.94%
Revenue NY rev (1m)-1.78%
Revenue NY rev (3m)-5.03%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.54
P/FCF N/A
P/OCF N/A
P/B 0.16
P/tB 0.76
EV/EBITDA 19.51
EPS(TTM)-0.38
EYN/A
EPS(NY)-0.22
Fwd EYN/A
FCF(TTM)-0.12
FCFYN/A
OCF(TTM)-0.07
OCFYN/A
SpS1.12
BVpS3.69
TBVpS0.79
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -27.79%
ROE -34.64%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 30.88%
FCFM N/A
ROA(3y)-16.09%
ROA(5y)-22.56%
ROE(3y)-20.59%
ROE(5y)-49.37%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y34.12%
GM growth 5Y-3.12%
F-Score4
Asset Turnover0.24
Health
Industry RankSector Rank
Debt/Equity 0.11
Debt/FCF N/A
Debt/EBITDA 12.7
Cap/Depr 27.68%
Cap/Sales 4.39%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.62
Quick Ratio 1.61
Altman-Z -0.77
F-Score4
WACC8.65%
ROIC/WACCN/A
Cap/Depr(3y)20.35%
Cap/Depr(5y)159.29%
Cap/Sales(3y)4.15%
Cap/Sales(5y)16.15%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)25.41%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%20%
EPS Next Y-222.48%
EPS Next 2Y17.62%
EPS Next 3Y21.07%
EPS Next 5Y17.04%
Revenue 1Y (TTM)11.23%
Revenue growth 3Y55.33%
Revenue growth 5Y78.86%
Sales Q2Q%-1.36%
Revenue Next Year8.45%
Revenue Next 2Y7.11%
Revenue Next 3Y5.97%
Revenue Next 5Y5.9%
EBIT growth 1Y-239.61%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year135.61%
EBIT Next 3Y37.38%
EBIT Next 5Y22.99%
FCF growth 1Y-24.49%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y9.12%
OCF growth 3YN/A
OCF growth 5YN/A